These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1898886)

  • 1. Alterations in luteal phase progesterone and estradiol production after leuprolide acetate therapy before ovarian stimulation for in vitro fertilization.
    Brzyski RG; Jones GS; Jones HW; Oehninger S; Muasher SJ
    Fertil Steril; 1991 Jan; 55(1):119-24. PubMed ID: 1898886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.
    Droesch K; Muasher SJ; Brzyski RG; Jones GS; Simonetti S; Liu HC; Rosenwaks Z
    Fertil Steril; 1989 Feb; 51(2):292-7. PubMed ID: 2492234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.
    Serafini P; Stone B; Kerin J; Batzofin J; Quinn P; Marrs RP
    Fertil Steril; 1988 Jan; 49(1):90-5. PubMed ID: 3121401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval.
    de Ziegler D; Cedars MI; Randle D; Lu JK; Judd HL; Meldrum DR
    Fertil Steril; 1987 Nov; 48(5):807-10. PubMed ID: 3117592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.
    Edelstein MC; Brzyski RG; Jones GS; Oehninger S; Sieg SM; Muasher SJ
    J In Vitro Fert Embryo Transf; 1990 Jun; 7(3):172-6. PubMed ID: 2116488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.
    Gelety TJ; Pearlstone AC; Surrey ES
    Fertil Steril; 1995 Dec; 64(6):1074-80. PubMed ID: 7589655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.
    Gelety TJ; Surrey ES
    J Assist Reprod Genet; 1997 Oct; 14(9):525-30. PubMed ID: 9401871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization.
    Garcia JE; Padilla SL; Bayati J; Baramki TA
    Fertil Steril; 1990 Feb; 53(2):302-5. PubMed ID: 2105247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J; Creus M; Fábregues F; Carmona F; Casamitjana R; Peñarrubia J; Rivera F; Vanrell JA
    Gynecol Endocrinol; 1995 Mar; 9(1):51-8. PubMed ID: 7793300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization.
    San Roman GA; Surrey ES; Judd HL; Kerin JF
    Fertil Steril; 1992 Oct; 58(4):744-9. PubMed ID: 1426320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study of the controlled ovarian hyperstimulation using GnRH agonist and pure FSH in in vitro fertilization-embryo transfer and gamete intrafallopian transfer program].
    Usui A
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1431-8. PubMed ID: 2511261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles.
    Tavaniotou A; Devroey P
    Reprod Biomed Online; 2006 Sep; 13(3):326-30. PubMed ID: 16984758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantation and pregnancy rates in relation to oestradiol and progesterone profiles in cycles with and without the use of gonadotrophin-releasing hormone agonist suppression.
    Hassiakos D; Toner JP; Muasher SJ; Jones HW
    Hum Reprod; 1990 Nov; 5(8):1004-8. PubMed ID: 2127937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.